NeurologyOnline.net

Neurology Xagena

Xagena Mappa
Medical Meeting
Farmaexplorer.it
Neurobase.it

Parkinson's disease associated with reduced risk of prostate cancer


Prostate cancer growth and progression may be linked to neurogenesis and to medical anti- Parkinson treatment, but results are inconclusive. Therefore, researchers have examined the association between Parkinson's disease and risk of prostate cancer in a population based case-control study.

45,429 patients diagnosed with incident prostate cancer during 1997-2010 from the National Cancer Registry were identified.
Five age-matched population controls ( n=227,145 ) were selected for each case.

The analyses were stratified by duration of Parkinson's disease and stage of prostate cancer ( localized and advanced ).

In total, 245 patients ( 0.5% ) and 1656 controls ( 0.7% ) had Parkinson's disease.

Overall, patients with Parkinson's disease had a 27% lower risk of prostate cancer compared with patients without Parkinson's disease ( adjusted OR, ORa=0.73; 95% confidence interval ( CI ), 0.63-0.83 ).

Risk of prostate cancer decreased with increasing duration of Parkinson's disease.

The odds ratios were slightly lower for advanced prostate cancer ( ORa=0.68; 95% CI, 0.52-0.88 ) than for localized prostate cancer ( ORa 0.76; 95% CI, 0.61-0.93 ).

In conclusion, Parkinson's disease was associated with a risk reduction overall ( 27% ), which decreased with increasing duration of Parkinson's disease. ( Xagena )

Jespersen CG et al, Cancer Epidemiol 2016;45:157-161

XagenaMedicine_2016



Indietro